AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteARL-15896 is a novel N-methyl-D-aspartate receptor ion channel antagonist.
More Information Supplier PageARL-15896 is a novel N-methyl-D-aspartate receptor ion channel antagonist.
More Information Supplier PageArmodafinil is the R isomer and longer-lasting isomer of racemic modafinil.
More Information Supplier PageArmodafinil is the R isomer and longer-lasting isomer of racemic modafinil.
More Information Supplier PageArmodafinil is the R isomer and longer-lasting isomer of racemic modafinil.
More Information Supplier PageArmodafinil is the R isomer and longer-lasting isomer of racemic modafinil.
More Information Supplier PageARN-509 is an androgen receptor antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes.
More Information Supplier PageARN-509 is an androgen receptor antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes.
More Information Supplier PageARN-509 is an androgen receptor antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes.
More Information Supplier PageARN-509 is an androgen receptor antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes.
More Information Supplier PageARN-509 is an androgen receptor antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes.
More Information Supplier PageARP 100 is a selective inhibitor of matrix metalloproteinases 2 (MMP-2) with IC50 value of 12 nM.
More Information Supplier PageARP 100 is a selective inhibitor of matrix metalloproteinases 2 (MMP-2) with IC50 value of 12 nM.
More Information Supplier PageARP 100 is a selective inhibitor of matrix metalloproteinases 2 (MMP-2) with IC50 value of 12 nM.
More Information Supplier PageARP 101, selective inhibitor of MMP-2 that displays ~ 600-fold selectivity over MMP-1 (IC50 values are 0.81 and 486 nM respectively).
More Information Supplier PageARP 101, selective inhibitor of MMP-2 that displays ~ 600-fold selectivity over MMP-1 (IC50 values are 0.81 and 486 nM respectively).
More Information Supplier PageARP 101, selective inhibitor of MMP-2 that displays ~ 600-fold selectivity over MMP-1 (IC50 values are 0.81 and 486 nM respectively).
More Information Supplier PageARQ-197 is a selective inhibitor of the c-Met receptor tyrosine kinase
More Information Supplier PageARQ-197 is a selective inhibitor of the c-Met receptor tyrosine kinase
More Information Supplier PageARQ-197 is a selective inhibitor of the c-Met receptor tyrosine kinase
More Information Supplier PageARQ-197 is a selective inhibitor of the c-Met receptor tyrosine kinase
More Information Supplier PageARQ 621 is an allosteric, and selective Eg5 mitotic motor protein inhibitor.
More Information Supplier PageARQ 621 is an allosteric, and selective Eg5 mitotic motor protein inhibitor.
More Information Supplier PageARQ 621 is an allosteric, and selective Eg5 mitotic motor protein inhibitor.
More Information Supplier PageARQ 621 is an allosteric, and selective Eg5 mitotic motor protein inhibitor.
More Information Supplier PageARRY-380 is an ErbB-2 inhibitor that selectively binds to and inhibits the phosphorylation of ErbB-2, resulting in growth inhibition and death of ErbB-2-expressing tumor cells.
More Information Supplier PageARRY-380 is an ErbB-2 inhibitor that selectively binds to and inhibits the phosphorylation of ErbB-2, resulting in growth inhibition and death of ErbB-2-expressing tumor cells.
More Information Supplier PageARRY-380 is an ErbB-2 inhibitor that selectively binds to and inhibits the phosphorylation of ErbB-2, resulting in growth inhibition and death of ErbB-2-expressing tumor cells.
More Information Supplier PageARRY-380 is an ErbB-2 inhibitor that selectively binds to and inhibits the phosphorylation of ErbB-2, resulting in growth inhibition and death of ErbB-2-expressing tumor cells.
More Information Supplier PageARRY-380 is an ErbB-2 inhibitor that selectively binds to and inhibits the phosphorylation of ErbB-2, resulting in growth inhibition and death of ErbB-2-expressing tumor cells.
More Information Supplier PageKSP inhibitor ARRY-520 specifically inhibits KSP (kinesin-5 or Eg5) with potential antineoplastic activity.
More Information Supplier PageKSP inhibitor ARRY-520 specifically inhibits KSP (kinesin-5 or Eg5) with potential antineoplastic activity.
More Information Supplier PageKSP inhibitor ARRY-520 specifically inhibits KSP (kinesin-5 or Eg5) with potential antineoplastic activity.
More Information Supplier PageKSP inhibitor ARRY-520 specifically inhibits KSP (kinesin-5 or Eg5) with potential antineoplastic activity.
More Information Supplier PageARRY-520 R enantiomer is the R form of ARRY-520, which is a synthetic, small molecule kinesin spindle protein (KSP) inhibitor with IC50 of 6 nM.
More Information Supplier PageARRY-520 R enantiomer is the R form of ARRY-520, which is a synthetic, small molecule kinesin spindle protein (KSP) inhibitor with IC50 of 6 nM.
More Information Supplier PageARRY-520 R enantiomer is the R form of ARRY-520, which is a synthetic, small molecule kinesin spindle protein (KSP) inhibitor with IC50 of 6 nM.
More Information Supplier PageARRY-543 is a novel, oral ErbB family inhibitor that, unlike approved ErbB inhibitors, targets all members of the ErbB family, including ErbB3, either directly or indirectly, and has potential advantages in treating tumors that signal through multiple ErbB family members.
More Information Supplier PageARRY-543 is a novel, oral ErbB family inhibitor that, unlike approved ErbB inhibitors, targets all members of the ErbB family, including ErbB3, either directly or indirectly, and has potential advantages in treating tumors that signal through multiple ErbB family members.
More Information Supplier PageARRY-543 is a novel, oral ErbB family inhibitor that, unlike approved ErbB inhibitors, targets all members of the ErbB family, including ErbB3, either directly or indirectly, and has potential advantages in treating tumors that signal through multiple ErbB family members.
More Information Supplier PageARRY-543 is a novel, oral ErbB family inhibitor that, unlike approved ErbB inhibitors, targets all members of the ErbB family, including ErbB3, either directly or indirectly, and has potential advantages in treating tumors that signal through multiple ErbB family members.
More Information Supplier PageARRY334543 is a potent, orally active small molecule inhibitor of EGFR and ErbB-2.
More Information Supplier PageARRY334543 is a potent, orally active small molecule inhibitor of EGFR and ErbB-2.
More Information Supplier PageARRY334543 is a potent, orally active small molecule inhibitor of EGFR and ErbB-2.
More Information Supplier PageARRY334543 is a potent, orally active small molecule inhibitor of EGFR and ErbB-2.
More Information Supplier PageArtemether has been shown to have significant anticancer and antitumor activities. It is demonstrated that artemether caused strong inhibitory effects on brain glioma growth and angiogenesis in rats.
More Information Supplier PageArtemether has been shown to have significant anticancer and antitumor activities. It is demonstrated that artemether caused strong inhibitory effects on brain glioma growth and angiogenesis in rats.
More Information Supplier Page
